Claims
- 1. A method for extending the lifetime of a therapeutic agent of interest having a molecular weight of less than 5 kDa, said method comprising:
- administering to the vascular system of a mammalian host a compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds, said reactive functional group being joined to said therapeutic agent of interest, whereby said reactive functional group reacts with at least one of mobile protein and cells of the vascular system to produce at least one of modified mobile protein and modified cells, wherein said reactive functional group reacts with a functional group on said protein or cells to form a member of the group consisting of amide, ester, imine, thioether, disulfide and substituted amine:
- wherein said therapeutic agent of interest is added in an amount effective to achieve its therapeutic function over an extended period of time.
- 2. A method according to claim 1, wherein said agent of interest is a synthetic peptide.
- 3. A method according to claim 1, wherein said protein is a glycoprotein.
- 4. A method according to claim 1, wherein said agent of interest is a naturally occurring compound.
- 5. A method according to claim 1, wherein said agent of interest is a synthetic organic compound.
- 6. A method according to claim 1, wherein said reactive functional group is a carboxylate ester which reacts with amines in an aqueous medium to form amides.
- 7. A method for extending the lifetime of a naturally occurring organic compound having a molecular weight of less than 5 Kda, said method comprising:
- administering to the vascular system of a mammalian host a compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds, said reactive functionaal group being joined to said naturally occurring organic compound, where said naturally occurring compound is a therapeutic agent whereby said reactive functional group is a carboxylate ester which reacts with at least one of mobile protein and cells of the vascular system to produce at least one of modified mobile protein and modified cells, wherein said naturally occurring compound is added in an amount effective to achieve its therapeutic function over an extended period of time.
- 8. A method for extending the lifetime of a therapeutic agent of interest having a molecular weight of less than about 2.5 kDa, said method comprising:
- administering to the vascular system of a mammalian host a compound, said compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds wherein said reactive functional group is joined to said therapeutic agent of interest, whereby said reactive functional group reacts with at least one of mobile proteins or cells of the vascular system to produce one of modified mobile proteins or modified cells, wherein said functional group reacts with a functional group on said protein or cell to form a member of the group consisting of amide, ester, imine, thioether, disulfide or substituted amine;
- wherein said therapeutic agent of interest is added in an amount to maintain an effective therapeutic concentration over an extended period of time.
- 9. A method according to claim 8, wherein said functional group is a carboxylate ester which forms an amide.
- 10. A method according to claim 8, wherein said agent of interest is a synthetic peptide.
- 11. A method according to claim 8, wherein said mobile protein is a glycoprotein.
- 12. A method according to claim 8, wherein said agent of interest is a naturally occurring compound.
- 13. A method according to claim 8, wherein said agent of interest is a synthetic organic compound.
- 14. A method according to claim 8, wherein said reactive functional group is a carboxylate ester which reacts with amines in aqueous medium to form amides.
- 15. A method for extending the lifetime of a naturally occurring organic compound having a molecular weight of less than about 5 kDa, said method comprising:
- administering a bolus to the vascular system of a mammalian host a compound, said compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds wherein said reactive functinonal group is joined to said naturally occurring organic compound, wherein said naturally occurring organic compound is a therapeutic agent, whereby said reactive functional group reacts with at least one of mobile proteins and cells of the vascular system to produce one of modified mobile proteins or modified cells, wherein said functional group reacts with a functional group on said protein or cell to form a member of the group consisting of amide, ester, imine, thioether, disulfide or substituted amine;
- wherein said naturally occurring compound is added in an amount to maintain an effective therapeutic concentration over an extended period of time.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 08/137,821, filed Oct. 15, 1993, which application was a continuation-in-part of application Ser. No. 08/070,092, filed May 27, 1993, which was a continuation-in-part of application Ser. No. 07/592,214, filed Oct.3, 1990.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4971792 |
Steplewski et al. |
Nov 1990 |
|
Non-Patent Literature Citations (5)
Entry |
Tao et al. The Journal o f Immunology vol. 143 No. 8 Oct. 15, 1989 p. 2595. |
Gillies et al. Human Antibodies and Hybridomas. 1990 vol. 1 No. 1 p. 47. |
Burgess et al. Journal of Cell Biology Vol. IIII Nov. 1990 2129. |
Ghose et al. J.N. Cancer Inst 61(3) 1978 p. 657. |
Coller et al., "Thromboerythrocytes," J. Clin. Invest. (1992) 89:546-555. |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
137821 |
Oct 1993 |
|
Parent |
70092 |
May 1993 |
|
Parent |
592214 |
Oct 1990 |
|